BP000136-C088: Recombinant Mouse IL-13
Source: E. coli-derived.
The ED50 of rmIL13 as determined by dose-dependent stimulation of proliferation of TF-1 human erythroleukemic cells was < 2 ug/ml, corresponding to a Specific Activity of 5.0 x 105 IU/mg.
Purity > 95%, by reducing SDS-PAGE and SEC-HPLC.
Endotoxin: Less than 0.1 ng/ug (1 EU/ug).BP000136-CYT-375: Recombinant Mouse IL-13
Source: E. coli-derived.
A single, non-glycosylated polypeptide chain containing 110 amino acids and having a molecular mass of 12 kDa.
The ED50 range=2-6 ug/ml corresponding to a specific activity of 0.17-0.5 MU/mg, determined by the dose dependent prolifiration of TF-1 cells.
Purity > 95%, by SDS-PAGE.BP000136-CYT-391: Recombinant Rat IL-13
Source: E. coli-derived.
Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 10-100 ug/ml corresponding to a Specific Activity of 10,000-100,000 IU/mg.
Purity > 95%, by SDS-PAGE.BP000136-CYT-446: Recombinant Human IL-13
Source: E. coli-derived.
The ED50 was determined by the dose dependent prolifiration of TF-1 cells and was found to be < 1 ug/ml, corresponding to a specific activity of 1 MIU/mg.
Purity > 95%, by SDS-PAGE and RP-HPLC.BP000136-CYT-489: Recombinant Human IL-13, His Tag
Source: E. coli-derived.
Purity > 95%, by SDS--PAGE and RP-HPLC.BP000136-CYT-682: Recombinant Human IL-13 Variant
Source: E. coli-derived.
The ED50 was determined by the dose dependent prolifiration of TF-1 cells and was found to be < 1 ug/ml, corresponding to a specific activity of >1,000,000 units/mg. This analog has also been shown to exhibit increased in vivo activity compared to wild type IL-13.
Purity > 95%, by SDS--PAGE and RP-HPLC.